CHEBI:10033 - warfarin

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name warfarin
ChEBI ID CHEBI:10033
Definition A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.
Stars This entity has been manually annotated by the ChEBI Team.
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Roles Classification
Biological Role(s): EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
An EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitor that interferes with the action of NAD(P)H dehydrogenase (quinone), EC 1.6.5.2.
vitamin K antagonist
A class of anticoagulants which act by inhibiting the action of vitamin K.
Application(s): anticoagulant
An agent that prevents blood clotting.
rodenticide
A substance used to destroy rodent pests.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing warfarin (CHEBI:10033) has part (R)-warfarin (CHEBI:87737)
warfarin (CHEBI:10033) has part (S)-warfarin (CHEBI:87738)
warfarin (CHEBI:10033) has role anticoagulant (CHEBI:50249)
warfarin (CHEBI:10033) has role EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor (CHEBI:50390)
warfarin (CHEBI:10033) has role rodenticide (CHEBI:33288)
warfarin (CHEBI:10033) has role vitamin K antagonist (CHEBI:55347)
warfarin (CHEBI:10033) is a racemate (CHEBI:60911)
warfarin (CHEBI:10033) is conjugate acid of warfarin(1−) (CHEBI:50393)
Incoming warfarin(1−) (CHEBI:50393) is conjugate base of warfarin (CHEBI:10033)
IUPAC Name
rac-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
INNs Sources
warfarin ChemIDplus
warfarina ChemIDplus
warfarine ChemIDplus
warfarinum ChemIDplus
Synonyms Sources
(+/-)-Warfarin NIST Chemistry WebBook
(Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarine ChemIDplus
(RS)-Warfarin NIST Chemistry WebBook
1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone ChemIDplus
2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)- ChemIDplus
3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin ChemIDplus
3-(Acetonylbenzyl)-4-hydroxycoumarin NIST Chemistry WebBook
3-(Alpha-acetonylbenzyl)-4-hydroxycoumarin NIST Chemistry WebBook
3-(alpha-Phenyl-beta-acetylaethyl)-4-hydroxycumarin ChemIDplus
3-(alpha-Phenyl-beta-acetylethyl)-4-hydroxycoumarin ChemIDplus
4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-cumarin ChemIDplus
4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin ChEBI
Coumafene ChemIDplus
DL-3-(α-acetonylbenzyl)-4-hydroxycoumarin NIST Chemistry WebBook
DL-warfarin ChEBI
rac-warfarin ChEBI
racemic warfarin ChEBI
Zoocoumarin ChemIDplus
Brand Name Source
Warf 10 DrugBank
Manual Xrefs Databases
C01541 KEGG COMPOUND
D08682 KEGG DRUG
DB00682 DrugBank
HMDB0001935 HMDB
US2427578 Patent
US2765321 Patent
US2777859 Patent
US3239529 Patent
Warfarin Wikipedia
View more database links
Registry Numbers Types Sources
1293536 Reaxys Registry Number Reaxys
1293536 Beilstein Registry Number Beilstein
81-81-2 CAS Registry Number KEGG COMPOUND
81-81-2 CAS Registry Number ChemIDplus
81-81-2 CAS Registry Number NIST Chemistry WebBook
Citations Waiting for Citations Types Sources
13358873 PubMed citation Europe PMC
15578879 PubMed citation Europe PMC
18294321 PubMed citation Europe PMC
19294412 PubMed citation Europe PMC
24478171 PubMed citation Europe PMC
24973057 PubMed citation Europe PMC
25022924 PubMed citation Europe PMC
25023204 PubMed citation Europe PMC
25393417 PubMed citation Europe PMC
25466603 PubMed citation Europe PMC
25534862 PubMed citation Europe PMC
25537751 PubMed citation Europe PMC
25555316 PubMed citation Europe PMC
25683623 PubMed citation Europe PMC
25757926 PubMed citation Europe PMC
25823787 PubMed citation Europe PMC
25828628 PubMed citation Europe PMC
25830869 PubMed citation Europe PMC
25842804 PubMed citation Europe PMC
25845131 PubMed citation Europe PMC
25986145 PubMed citation Europe PMC
26114209 PubMed citation Europe PMC
26142522 PubMed citation Europe PMC
26142525 PubMed citation Europe PMC
26203765 PubMed citation Europe PMC
26238769 PubMed citation Europe PMC
Last Modified
22 February 2017